CNX-774 M SE Currently it is in Phase

Currently it is in Phase II/III clinical trials for Hodgkin's lymphoma and advanced breast cancer

specifically inhibits this interaction by binding to c-Myc

PF-06282999 is moderately bound to plasma proteins across preclinical species and humans

a unique mucolytic antioxidant

Both c-Kit and VEGFR2 are overexpressed in a variety of cancers

CNX-774 M SE Currently it is in PhaseCNX 774 is a potent Btk inhibitor (IC50 < 1 nM). Recently Bruton's tyrosine kinase (BTK) , a crucial terminal kinase enzyme in the B cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders. Product information CAS Number: 1202759 32 7 Molecular Weight: 499. 50 Formula: C26H22FN7O3 Chemical Name: 4 {4 [(5 fluoro 4 {[3 (prop 2